Nano-Mediated Computational Framework for Pre-Symptomatic Detection Based on Computed Aided Alpha-Synuclein Analysis

Abstract

This study investigates the molecular interaction mechanism between Alpha-synuclein where antibody complexes associated with Parkinson's disease, Alzheimer's disease, with related synucleinopathies using molecular docking, nanoscale structural superposition, and computational nano-biointerface optimization analyses. Alpha-synuclein is a 140-amino-acid intrinsically disordered neuronal protein with a molecular mass of approximately 14.46 kDa, an isoelectric point of pH 4.7, and a hydrodynamic radius of 3.2–3.8 nm. A total of 14 optimized docking nano-models, containing approximately 73 peptide substitutions, 88 antibody mutations, and over 161 molecular alterations, were systematically analyzed to evaluate nano-bio interactions, nano-assembly behavior, and receptor recognition mechanisms. Stable α-helical interaction domains were identified between residues 1–92, whereas residues 93–140 exhibited increased β-sheet propensity, conformational instability, and nanoscale structural flexibility. Hydrophobic substitutions including 37V, 40V, 48V, 55V, 63V, 71V, and 74V accounted for nearly 42–48% of peptide mutations, while charged residues such as 28E, 35E, 43K, 58K, and 83E contributed approximately 25–30% of electrostatic nano-interface interactions. Aggregation kinetics increased by approximately 200–350% following a 1.5–2.5-fold elevation in α-synuclein expression, while oxidative nano-stress enhanced oligomer formation by nearly 300–500%. Furthermore, cross-seeding interactions with Beta-amyloid peptide isoforms Aβ40 and Aβ42 accelerated fibrillation kinetics by approximately 250–400%. Neurotoxicity studies demonstrated reductions in mitochondrial activity of 30–60%, increases in reactive oxygen species of 200–500%, increases in Ca²⁺ influx of 150–300%, and neuronal viability losses of 40–70%. These findings provide quantitative insight into α-synuclein nano-bio interface interactions and support the development of nanomaterials, nano-biosensors, nano-diagnostics, nano-Immunotherapeutics, nano-carriers, nanoelectronics, nanomedicine platforms, and precision nano-engineeringstrategies for neurodegenerative disease detection and targeted therapeutic delivery.